This week’s postings include:
Top News from EASL 2011: Here are a few highlights:
Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment.
FDA Fast Track designations granted for both the protease inhibitor BI 201335 plus standard-of-care and the interferon-free combination of BI 201335 with polymerase inhibitor, BI 207127.
PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a.
First Vaccine For Viral Hepatitis C Could Become A Reality.
April 2011 HCV Advocate newsletter that includes:
- Why We Should Test—Editorial: Testing everyone for HCV regardless of medical coverage is a very contentious issue, Now that we will have new response-guided treatment regimens and rapid testing, it may be time to take another look.
- HCV Snapshots this month is a pot pourri of interesting items from Silibinin monotherapy to IL28B Genomic-based Treatment Paradigms.
- Liver Transplantation: HCV Recurrence and Treatment, by Liz Highleyman, is a must read.
- HEALTHWISE: Humor, Health, and Hepatitis C is yet another delightful essay, by Lucinda K. Porter, RN., on living with hepatitis C.
April HBV Journal Review that includes:
- Rate of HBV drops in the U.S.
- Screening All Chemotherapy Patients for Hepatitis B.
- Connections between Hepatitis B and Diabetes.
- Biopsy and Treatment Recommended in HBeAg-negative Patients.
- Immunization at Birth Reduces Infection, but Parents May Still Transmit Infection.
- HIV-HBV Coinfected Face Higher Death Rates than HIV-HCV Coinfected.
New Hepatitis & Tattos Blog: Be sure to check out and participate in our new blog.
Don’t forget to check out our HCV & HBV Advocate Hepatitis Blog for more about the most recent news stories.
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to firstname.lastname@example.org
**To receive the eblast in your email inbox simply send an e-mail to: email@example.com with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.